{"prompt": "['SANOFI', 'AMENDED CLINICAL TRIAL PROTOCOL 03', 'COMPOUND: DUPILUMABISAR231893', 'A randomized, double-blind, placebo-controlled, parallel group study to evaluate', 'the efficacy and safety of dupilumab in children 6 to <12 years of age with', 'uncontrolled persistent asthma', 'STUDY NUMBER: EFC14153', 'VERSION DATE / STATUS: 18 October 2019 / Final', 'NCT02948959', 'Version Number:', '1', 'EudraCT', '2016-001607-23', 'IND Number', '105379', 'WHO universal trial number:', 'U1111-1179-4851', 'Date:', '18-Oct-2019', 'Total number of pages:', '182', 'Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its', 'affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be', 'disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written', 'consent of Sanofi (or the concerned affiliated company); \"affiliated company\\' means any corporation, partnership or other entity which at the date', \"of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with 'control' meaning\", 'direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity', 'According to template: QSD-003152 VERSION N\u00b03.0 (04-FEB-2016)', 'Page 1', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'NAMES AND ADDRESSES OF', 'COORDINATING', 'Name:', 'INVESTIGATOR', 'Address:', 'Tel:', 'Fax:', 'E-mail:', \"MONITORING TEAM'S\", 'Name:', 'REPRESENTATIVE', 'Address:', 'Tel:', 'Fax:', 'E-mail:', 'SPONSOR', 'Company:', 'Address:', 'OTHER EMERGENCY', 'TELEPHONE NUMBERS', 'Property of the Sanofi Group - strictly confidential', 'Page 2', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', 'DOCUMENT HISTORY', 'Document', 'Country/Countries', 'Date, version', 'impacted by amendment', 'Amended Clinical Trial Protocol 03', 'All', '18-Oct-2019, version 1 (electronic 6.0)', 'Amended Clinical Trial Protocol 02', 'All', '18-Jun-2018, version 1 (electronic 5.0)', 'Protocol Amendment 03', 'All', '18-Jun-2018, version 1 (electronic 4.0)', 'Amended Clinical Trial Protocol 02', 'Brazil', '02-Feb-2018, version 1 (electronic 1.0)', 'Protocol Amendment 02', 'Brazil', '02-Feb-2018, version 1 (electronic 1.0)', 'Amended Clinical Trial Protocol 01', 'All', '10-Mar-2017, version 1 (electronic 1.0)', 'Protocol Amendment 01', 'All', '10-Mar-2017, version 1 (electronic 1.0)', 'Original Protocol', '04-Aug-2016, version 1 (electronic 1.0)', 'AMENDED PROTOCOL 03 (18 October 2019)', 'This amended protocol (amendment 03) is considered to be substantial based on the criteria set', 'forth in Article 10 (a) of Directive 2001/20/EC of the European Parliament and the Council of the', 'European Union.', 'OVERALL RATIONALE FOR THE AMENDMENT', 'To change the study primary efficacy analysis population from an overall uncontrolled persistent', 'asthma population to the subpopulation with evidence of either asthma with an eosinophilic', 'phenotype or, more broadly, asthma with type 2 inflammatory phenotype. This is to be consistent', 'with the observed efficacy seen in the pivotal Study EFC13579 (QUEST) as well as approved', 'label indications for adults and adolescents with asthma.', 'Property of the Sanofi Group - strictly confidential', 'Page 3', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}